Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2010 Sep 15.

Published in final edited form as: Biochem Pharmacol. 2009 May 13;78(6):617–624. doi: 10.1016/j.bcp.2009.05.011

Table 3.

Pharmacokinetic parameters (mean ± SD) of harmaline determined by non-compartmental analysis using WinNonLin.

		Tg-CYP2D6				Wild-type

Parameters	Units	i.v. 5 mg/kg	i.v. 15 mg/kg	i.p. 5 mg/kg	i.p. 15 mg/kg	i.v. 5 mg/kg	i.v. 15 mg/kg	i.p. 5 mg/kg	i.p. 15 mg/kg
AUC_0→∞	min·μmol/L	134 ± 19	544 ± 10	94.3 ± 9.5	359 ± 15	233 ± 34^*	682 ± 114	175 ± 28^**	662 ± 39^***
CL	mL/min/kg	176 ± 27	128 ± 2	-	-	102 ± 16^*	104 ± 16	-	-
V_ss	L/kg	4.41 ± 0.08	5.14 ± 0.46	-	-	5.74 ± 1.02	6.23 ± 0.57	-	-
T_max	min	-	-	6.67 ± 2.89	8.33 ± 5.77	-	-	5.83 ± 3.82	15.0 ± 5.0
C_max	μmol/L	-	-	3.82 ± 1.04	11.0 ± 1.0	-	-	3.02 ± 0.25	11.5 ± 1.3
t_1/2	min	18.0 ± 2.9	36.5 ± 3.3	17.8 ± 2.7	19.1 ± 3.5	41.9 ± 11.7^*	43.1 ± 9.6	32.3 ± 10.7	35.5 ± 5.1^*
F	%	-	-	68.6 ± 16.6	60.0 ± 2.4	-	-	73.7 ± 20.5	98.2 ± 10.1

^*

p<0.05,

^**

p<0.01,

^***

p<0.001 compared with the corresponding values in Tg-CYP2D6 mice receiving the same treatment.